[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Joshi NP, Haresh KP, Das P, Kumar R, Prabhakar R, Sharma DN, Heera P, Julka PK, Rath GK: Unresectable basaloid squamous cell carcinoma of the trachea treated with concurrent chemoradiotherapy: a case report with review of literature. J Cancer Res Ther; 2010 Jul-Sep;6(3):321-3
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unresectable basaloid squamous cell carcinoma of the trachea treated with concurrent chemoradiotherapy: a case report with review of literature.
  • Basaloid squamous cell carcinoma is an uncommon variant of squamous cell carcinoma of the trachea.
  • We describe the case of an unresectable basaloid squamous cell carcinoma of the trachea treated with concurrent chemoradiotherapy up to a dose of 60 Gy in 33 fractions with weekly paclitaxel and carboplatin.
  • The pathological recognition of basaloid squamous cell carcinoma and its distinction from adenoid cystic carcinoma of the trachea is important for its management.
  • Combining systemic chemotherapy with locoregional radiation is a logical approach to treatment, especially for the basaloid squamous cell carcinoma of the trachea, given its tendency to metastasize early after definitive therapy.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Tracheal Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119264.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


2. Thotathil ZS, Agarwal JP, Shrivastava SK, Dinshaw KA: Primary malignant tumors of the trachea - the Tata Memorial Hospital experience. Med Princ Pract; 2004 Mar-Apr;13(2):69-73

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant tumors of the trachea - the Tata Memorial Hospital experience.
  • OBJECTIVE: Primary tumors of the trachea are extremely rare.
  • Treatment methods vary considerably and few studies have sought to provide adequate guidelines.
  • This study reviews the records of patients treated for tracheal cancer at the Tata Memorial Hospital (TMH), Mumbai, India.
  • SUBJECTS AND METHODS: Fifteen patients with primary tracheal malignancies were identified in the TMH database during the period from 1983 to 2000.
  • Squamous cell carcinoma was the commonest histologic subtype (40%) followed by adenoid cystic carcinoma (27%).
  • Ten patients received radical treatment.
  • Another was explored but was found to be unresectable and was 1 of 2 patients treated with chemotherapy and radiotherapy.
  • The majority of patients (8/9) were treated with locoregional fields and doses ranging from 40 to 60 Gy (median 50 Gy).
  • Two patients also received intraluminal brachytherapy, 1 as part of initial treatment and another for recurrence.
  • Follow-up times ranged from 1 month to 134 months, median of 38 months.
  • CONCLUSION: Tracheal cancer is a rare malignancy.
  • Radiation therapy is a reasonably effective modality for unresectable disease.
  • [MeSH-major] Tracheal Neoplasms / epidemiology
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Kuwait / epidemiology. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 S. Karger AG, Basel
  • (PMID = 14755137.001).
  • [ISSN] 1011-7571
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


3. Baconnier M, Phélip JM, Germain E, Durand A, Balosso J, Bichard P, Roblin X: [External radiotherapy and photodynamic therapy for esophageal carcinoma: a dangerous association?]. Gastroenterol Clin Biol; 2008 Mar;32(3):221-3
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [External radiotherapy and photodynamic therapy for esophageal carcinoma: a dangerous association?].
  • [Transliterated title] Radiothérapie externe et photothérapie dynamique des cancers de l'oesophage: une association dangereuse ?
  • A 60-year-old man presented an oesophageal transmural necrosis fistulised in the trachea following curative photodynamic therapy (PDT) for a superficial recurrence of an oesophageal carcinoma, initially treated by radiochemotherapy.
  • Two stents, a tracheal and an oesophageal one, were placed.
  • [MeSH-major] Esophageal Neoplasms / therapy. Neoplasm Recurrence, Local / drug therapy. Photochemotherapy / adverse effects. Tracheoesophageal Fistula / etiology
  • [MeSH-minor] Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant. Dihematoporphyrin Ether / adverse effects. Humans. Male. Middle Aged. Necrosis. Photosensitizing Agents / adverse effects. Radiotherapy, Adjuvant. Stents

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18343070.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


Advertisement
4. Paulino AF, Singh B, Shah JP, Huvos AG: Basaloid squamous cell carcinoma of the head and neck. Laryngoscope; 2000 Sep;110(9):1479-82
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid squamous cell carcinoma of the head and neck.
  • OBJECTIVE/HYPOTHESIS: Basaloid squamous cell carcinoma (BSCC), an uncommon tumor with predilection for the upper aerodigestive tract, is a distinct variant of squamous carcinoma, because of its unique histological features and ominous clinical behavior.
  • Sites of origin included the larynx (4), tongue (3), pyriform sinus (3), nose (2), floor of mouth (2), mastoid (1), tonsil (1), epiglottis (1), nasopharynx (1), trachea (1), and palate (1).
  • Treatment modalities included surgery with or without chemotherapy or radiotherapy in 13 patients, chemotherapy with irradiation in 2, chemotherapy alone in 2, and radiotherapy alone in 3.
  • Four were alive with disease at the time of writing and five died of disease.
  • Greater number of patients must be studied and compared with age-matched and stage-matched controls of conventional squamous cell carcinoma to determine whether the poor clinical outcome is related more to high-stage presentation or to the tumor's high-grade malignant cytological features.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Head and Neck Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10983946.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


5. Nishimura M, Daiko H, Yoshida J, Nagai K: Salvage esophagectomy following definitive chemoradiotherapy. Gen Thorac Cardiovasc Surg; 2007 Nov;55(11):461-4; discussion 464-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage esophagectomy following definitive chemoradiotherapy.
  • OBJECTIVES: To evaluate the outcome of salvage surgery following definitive chemoradiotherapy (CRT) for locally advanced esophageal cancer.
  • METHODS: We reviewed patients undergoing salvage esophagectomy from August 2000 through April 2006 at the National Cancer Center Hospital East, following 5-fluorouracil and cisplatinum chemotherapy with concurrent radiotherapy over 50 Gy.
  • RESULTS: Forty-six patients (42 men, all with squamous cell carcinoma) underwent salvage surgery after full-dose concurrent chemoradiotherapy.
  • Operation time ranged from 257 to 602 min.
  • Postoperative complications were pneumonia in 5; anastmotic leakage in 10; wound infection in 3; anastomotic stenosis in 2; recurrent nerve palsy in 4; pyothorax in 2; multiple organ failure in 1; myocardial infarction in 1; trachea necrosis in 1.
  • The median survival time from salvage surgery was 12 months and that from CRT was 22 months.
  • [MeSH-major] Esophageal Neoplasms / surgery. Esophagectomy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Thorac Cardiovasc Surg. 1997 Nov;114(5):811-5; discussion 816 [9375611.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Oct;126(4):1168-73 [14566264.001]
  • [Cites] Ann Thorac Surg. 2003 Feb;75(2):337-41 [12607635.001]
  • [Cites] J Thorac Cardiovasc Surg. 2002 Aug;124(2):270-7 [12167786.001]
  • [Cites] JAMA. 1999 May 5;281(17):1623-7 [10235156.001]
  • [Cites] N Engl J Med. 1992 Jun 11;326(24):1593-8 [1584260.001]
  • [Cites] J Thorac Cardiovasc Surg. 2002 Jan;123(1):175-83 [11782772.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):425-33 [12957254.001]
  • (PMID = 18049854.001).
  • [ISSN] 1863-6705
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


6. Futami R, Tajiri T, Miyashita M, Maruyama H, Makino H, Nomura T, Tateno A, Miyashita T, Sasajima K: [Effect of nedaplatin, 5-FU, and leucovorin combined with radiation therapy in unresectable esophageal carcinoma]. Gan To Kagaku Ryoho; 2003 May;30(5):681-4
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of nedaplatin, 5-FU, and leucovorin combined with radiation therapy in unresectable esophageal carcinoma].
  • A 51-year-old male was assessed as having esophageal squamous cell carcinoma with trachea invasion and cervical lymph node metastasis.
  • After one course of chemotherapy using cisplatin (CDDP), 5-fluorouracil (5-FU) and Leucovorin (LV), the patient had progressive disease (PD) of the primary lesion and metastatic lymph nodes, and a side effect of severe nausea.
  • More information is needed as to whether changes in s-VEGF relate to the clinical effects of the treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy
  • [MeSH-minor] Combined Modality Therapy. Drug Administration Schedule. Endothelial Growth Factors / blood. Fluorouracil / administration & dosage. Humans. Intercellular Signaling Peptides and Proteins / blood. Leucovorin / administration & dosage. Lymphatic Metastasis. Lymphokines / blood. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Tracheal Neoplasms / pathology. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factors

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12795101.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Endothelial Growth Factors; 0 / Intercellular Signaling Peptides and Proteins; 0 / Lymphokines; 0 / Organoplatinum Compounds; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; 8UQ3W6JXAN / nedaplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Zhang ZM, Xu ZG, Tang PZ, Xue LY, Lü N: [A retrospective analysis of anaplastic thyroid carcinoma]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun;28(3):322-4
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A retrospective analysis of anaplastic thyroid carcinoma].
  • OBJECTIVE: To summarize the new knowledge of the anaplastic thyroid carcinoma (ATC).
  • METHODS: The clinical data of 58 patients (35 men, 23 women, aged 28 to 79 years) with ATC that were treated with various therapeutic modalities from 1981 to 2005 were retrospectively analyzed.
  • The dosage of postoperative radiotherapy was 40-70 Gy.
  • Only 2 patients received complete chemotherapy.
  • RESULTS: ATC invaded trachea in 40 patients (69.0%), esophagus in 32 patients (55.2%), and carotid in 17 patients (29.3%).
  • In postoperative radiation < 60 Gy subgroup , the 5-year survival rate was 19.3%; however, in > or = 60 Gy group, it was 53.7% (P = 0.0000).
  • Among all the 58 patients, some patients received palliative surgery because of tumor invasion in trachea (n = 16, 27.6%), esophagus (n = 8, 13.8%), carotid (n = 8, 13.8%), and other sites (n = 13, 22.4%).
  • Radical surgery and postoperative radiation > or = 60 Gy can improve the survival rate.
  • Tumor invasion in trachea, esophagus, and carotid are the main reasons of palliative surgery.
  • [MeSH-major] Carcinoma / surgery. Thyroid Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16900624.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


8. Ohta M, Sawabata N, Maeda H, Matsuda H: Efficacy and safety of tracheobronchoplasty after induction therapy for locally advanced lung cancer. J Thorac Cardiovasc Surg; 2003 Jan;125(1):96-100
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of tracheobronchoplasty after induction therapy for locally advanced lung cancer.
  • OBJECTIVES: Patients receiving induction therapy may have increased risk of morbidity and mortality after surgery.
  • We retrospectively evaluated the influence of preoperative treatment in patients who underwent sleeve resection for lung cancer.
  • Twenty patients received preoperative induction therapy; of them, 16 received induction chemoradiotherapy and 4 received only chemotherapy.
  • Twenty-eight patients underwent the procedure without adjuvant therapy.
  • RESULTS: The telescopic procedure was performed by placing sutures around the proximal and distal portions of the bronchial cartilage without wrapping the anastomosis.
  • Among the 20 patients who received induction therapy, pulmonary angioplasty was performed in 5 and chest wall resection was performed in 3.
  • Among the 28 patients without preoperative adjuvant therapy, pulmonary angioplasty was performed in 3, diaphragmatic resection was performed in 1, and chest wall resection was performed in 1.
  • Complications relating to the anastomosis occurred in 1 patient (5.0%) who received induction therapy; however, no operative deaths occurred.
  • Bronchoscopic examinations demonstrated that mucosal healing was prolonged in patients who underwent induction therapy.
  • CONCLUSION: Induction therapy did not significantly affect morbidity or mortality among patients who underwent sleeve resection.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery
  • [MeSH-minor] Angioplasty. Antineoplastic Agents / therapeutic use. Bronchi / surgery. Female. Humans. Male. Middle Aged. Preoperative Care. Radiotherapy Dosage. Retrospective Studies. Trachea / surgery

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Thorac Cardiovasc Surg. 2003 Nov;126(5):1670-1; author reply 1671 [14666066.001]
  • (PMID = 12538990.001).
  • [ISSN] 0022-5223
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


9. Ishiyama T, Aoyama T, Hirahara H, Iwashima A, Tsukada H, Souma T: [Successful resection of endotracheal metastatic lung cancer using percutaneous cardiopulmonary support system: a case report]. Kyobu Geka; 2001 Jan;54(1):19-23
Genetic Alliance. consumer health - Metastatic cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We experienced a rare case of endotracheal metastasis derived from squamous cell lung cancer.
  • Pathological diagnosis indicated stage IIB and he underwent two cycles of chemotherapy with CDDP + VDS.
  • Bronchofiberoptic examination showed same as CT finding and its brushing cytology confirmed squamous cell carcinoma.
  • Majority of the reported cases of endotracheal metastases were treated conservatively as radiation, laser and/or chemotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Cardiopulmonary Bypass / methods. Trachea / surgery. Tracheal Neoplasms / secondary. Tracheal Neoplasms / surgery
  • [MeSH-minor] Humans. Lung Neoplasms / pathology. Male. Middle Aged. Reconstructive Surgical Procedures. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11197904.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 16
  •  go-up   go-down


10. Hitzman CJ, Wattenberg LW, Wiedmann TS: Pharmacokinetics of 5-fluorouracil in the hamster following inhalation delivery of lipid-coated nanoparticles. J Pharm Sci; 2006 Jun;95(6):1196-211
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The inhalation delivery of 5-fluorouracil (5-FU) in lipid-coated nanoparticles (LNPs) to hamsters was evaluated to determine the feasibility for use in lung cancer chemotherapy.
  • The concentration of FITC-dextran and total 5-FU (released and LNP-associated) was determined as a function of time in the lung, trachea, larynx, esophagus, and serum.
  • Concentrations of 5-FU and FITC-dextran were initially high in the trachea, larynx, and esophagus, and lower in the lung.
  • An eight-compartment pharmacokinetic model was used to describe the observed trends in concentrations of LNPs and total 5-FU and to estimate the released 5-FU concentration in the above tissues.
  • [MeSH-minor] Administration, Inhalation. Aerosols. Animals. Carcinoma, Squamous Cell / drug therapy. Cricetinae. Delayed-Action Preparations. Dextrans / chemistry. Feasibility Studies. Fluorescein-5-isothiocyanate. Fluorescent Dyes. Lipids / chemistry. Lung Neoplasms / drug therapy. Male. Mesocricetus. Particle Size. Tissue Distribution

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc. and the American Pharmacists Association
  • (PMID = 16639722.001).
  • [ISSN] 0022-3549
  • [Journal-full-title] Journal of pharmaceutical sciences
  • [ISO-abbreviation] J Pharm Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aerosols; 0 / Antimetabolites, Antineoplastic; 0 / Delayed-Action Preparations; 0 / Fluorescent Dyes; 0 / Lipids; I223NX31W9 / Fluorescein-5-isothiocyanate; K3R6ZDH4DU / Dextrans; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Webb BD, Walsh GL, Roberts DB, Sturgis EM: Primary tracheal malignant neoplasms: the University of Texas MD Anderson Cancer Center experience. J Am Coll Surg; 2006 Feb;202(2):237-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary tracheal malignant neoplasms: the University of Texas MD Anderson Cancer Center experience.
  • BACKGROUND: Primary malignant neoplasms of the trachea are very rare and data relating to them are limited.
  • This study was conducted to review the presentation, management, and outcomes of primary tracheal cancers at our institution, a large multidisciplinary cancer center.
  • STUDY DESIGN: Retrospective chart review was conducted for all patients found to have a pathologic diagnosis of primary tracheal malignancy.
  • RESULTS: Since 1945, 74 patients were diagnosed with primary tracheal cancers.
  • Among these, 34 (45.9%) were squamous cell carcinomas, 19 (25.7%) were adenoid cystic carcinomas, and 21 (28.4%) were of other histologic types.
  • Most patients (77.3%) were former or current smokers, particularly those with squamous cell carcinoma (93.3%).
  • Patients who had adenoid cystic carcinoma and those with cervical primaries had better rates of disease-specific and overall survival than others (p = 0.036 and 0.006 for the former patient group and p = 0.006 and 0.030 for the latter patient group).
  • Among patients with incident disease treated at our institution (n = 45), those undergoing primary operation with adjuvant radiotherapy appeared to have better disease-specific and overall survival rates compared with those undergoing primary radiotherapy with or without chemotherapy (p = 0.0002 and 0.0003, respectively).
  • CONCLUSIONS: Primary tracheal cancers are very rare, and our results should be viewed with caution, given that our population comprised a small heterogeneous group treated over a 60-year period.
  • Although squamous cell carcinoma was the most common pathology in smokers, adenoid cystic carcinoma was more prevalent among nonsmokers.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Carcinoma, Squamous Cell / pathology. Tracheal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Comorbidity. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Smoking / epidemiology. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16427548.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Satyanarayana S, Pathak SD, Saraswat V, Sarma YS, Bharadwaj R, Goorha YK: Tracheal lymphoepithelioma-like carcinoma: a case report. Indian J Cancer; 2002 Jul-Sep;39(3):112-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tracheal lymphoepithelioma-like carcinoma: a case report.
  • Lymphoepithelioma like carcinoma is rare in locations other than nasopharynx.
  • We report the second case of this tumour in trachea, in a young female patient, who was managed with concomitent surgery, radiotherapy and chemotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Tracheal Neoplasms / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12928566.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


13. Oyama K, Hirosawa H, Ito H, Fukushima W, Masutani H, Kadoya N, Izumi R, Hirono T: [A case of advanced esophageal carcinoma successfully treated with chemoradiation therapy with low-dose cisplatin and 5-fluorouracil]. Gan To Kagaku Ryoho; 2000 Jun;27(6):899-903
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced esophageal carcinoma successfully treated with chemoradiation therapy with low-dose cisplatin and 5-fluorouracil].
  • We have experienced a case of advanced esophageal carcinoma successfully treated with chemoradiation therapy together with low-dose cisplatin and 5-fluorouracil, having only minor toxicity.
  • Cervical esophageal carcinoma was found to have invaded the larynx through endoscopy, and invasion to thyroid gland and trachea was suspected from a cervical CT.
  • We diagnosed the condition as advanced esophageal carcinoma (A2N(-)M0Pl0 Stage III).
  • We then treated the patient by chemoradiation therapy.
  • After the treatment, the carcinoma could not be detected by CT and endoscopy, and endoscopic biopsy revealed there were no active carcinoma cells.
  • The side effects of the therapy were very mild, therefore the patient could be discharged after a short time.
  • No evidence of a tumor relapse was found 5 months after the therapy.
  • We treated 4 patients with esophageal carcinoma using the same regimen, and the results of the therapy were 2 CR, 1 PR, and 1 PD, with an overall response rate of 75%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy
  • [MeSH-minor] Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Infusions, Intravenous. Male. Middle Aged. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10897218.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


14. Kagawa S, Ohtani S, Tanaka N, Fujiwara T: [A case of advanced non-small lung cancer responding to tumor suppressor p53 gene therapy]. Gan To Kagaku Ryoho; 2004 Oct;31(11):1788-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced non-small lung cancer responding to tumor suppressor p53 gene therapy].
  • The phase I study of the tumor suppressor p53 gene therapy for advanced lung cancer was performed.
  • A 57-year-old man with locally advanced squamous cell carcinoma at the tracheal bifurcation, clinical stage IIIB, had previously been treated by radiotherapy and chemotherapy.
  • He was treated by a local injection of ADVEXIN once every 4 weeks for 14 times without marked adverse events, which resulted in tumor regression and relief of his symptom for a year.
  • In conclusion, gene therapy with ADVEXIN may be an effective treatment for locally advanced non-small lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / therapy. Carcinoma, Squamous Cell / therapy. Genes, p53 / genetics. Genetic Therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15553716.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


15. Lo Galbo AM, de Bree R, Kuik DJ, Lips P, Leemans CR: Paratracheal lymph node dissection does not negatively affect thyroid dysfunction in patients undergoing laryngectomy. Eur Arch Otorhinolaryngol; 2010 May;267(5):807-10
MedlinePlus Health Information. consumer health - Hypothyroidism.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • From 1990 to 2004, 169 patients with a carcinoma of the larynx or hypopharynx who underwent paratracheal lymph node dissection were selected.
  • Patient, tumor and treatment characteristics were noted including age, gender, site, TNM stage and details of surgery, radiotherapy and chemotherapy.
  • All patients with hypo(para)thyroidism underwent various lymph node treatment modalities.
  • For the various treatment combinations, no increase of hypo(para)thyroidism was found if a bilateral paratracheal lymph node dissection was performed.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / therapy. Hypoparathyroidism / epidemiology. Hypoparathyroidism / physiopathology. Hypopharyngeal Neoplasms / epidemiology. Hypopharyngeal Neoplasms / therapy. Hypothyroidism / epidemiology. Hypothyroidism / physiopathology. Laryngectomy / methods. Lymph Node Excision
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Severity of Illness Index. Trachea / pathology. Trachea / radiation effects. Trachea / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2000 Jul-Aug;62(4):217-25 [10859523.001]
  • [Cites] Laryngoscope. 2005 May;115(5):894-8 [15867661.001]
  • [Cites] Laryngoscope. 2003 Sep;113(9):1595-9 [12972940.001]
  • [Cites] Arch Med Res. 2006 Jan;37(1):133-9 [16314199.001]
  • [Cites] Tumori. 2003 Sep-Oct;89(5):547-9 [14870783.001]
  • [Cites] Langenbecks Arch Surg. 2007 Jul;392(4):423-6 [17131155.001]
  • [Cites] Head Neck. 2008 Mar;30(3):336-40 [17636544.001]
  • [Cites] Acta Otorhinolaryngol Ital. 2007 Jun;27(3):123-5 [17883188.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2892-7 [11753963.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1997 Feb;22(1):7-12 [9088672.001]
  • [Cites] Acta Otolaryngol. 2007 Mar;127(3):312-7 [17364370.001]
  • [Cites] Acta Otolaryngol. 2007 Mar;127(3):318-22 [17364371.001]
  • [Cites] Qual Life Res. 1994 Oct;3(5):323-7 [7841966.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1999 Apr;24(2):104-8 [10225153.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2002 Apr;259(4):193-6 [12064507.001]
  • (PMID = 19915857.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Lott DG, Krakovitz PR: Squamous cell carcinoma associated with intralesional injection of cidofovir for recurrent respiratory papillomatosis. Laryngoscope; 2009 Mar;119(3):567-70
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma associated with intralesional injection of cidofovir for recurrent respiratory papillomatosis.
  • Intralesional injection of cidofovir has shown promise as an adjuvant therapy.
  • We report a case of invasive squamous cell cancer arising from squamous papilloma in a patient treated with multiple injections of cidofovir.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Carcinoma, Squamous Cell / chemically induced. Cytosine / analogs & derivatives. Neoplasms, Second Primary / chemically induced. Organophosphonates / adverse effects. Papilloma / drug therapy. Tracheal Neoplasms / drug therapy
  • [MeSH-minor] Child. Female. Follow-Up Studies. Humans. Injections, Intralesional / adverse effects. Otorhinolaryngologic Surgical Procedures / methods. Tomography, X-Ray Computed. Trachea / surgery

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Laryngoscope. 2010 Mar;120(3):650; author reply 651 [20013845.001]
  • (PMID = 19235765.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


17. Lin HW, Richmon JD, Emerick KS, de Venecia RK, Zeitels SM, Faquin WC, Lin DT: Malignant transformation of a highly aggressive human papillomavirus type 11-associated recurrent respiratory papillomatosis. Am J Otolaryngol; 2010 Jul-Aug;31(4):291-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of a highly aggressive human papillomavirus type 11-associated recurrent respiratory papillomatosis.
  • OBJECTIVE: The objective is to present an uncommon case of squamous cell carcinoma (SCC) arising from extensive recurrent respiratory papillomatosis (RRP) involving the upper and lower airway and temporal bone.
  • METHODS: We describe a case of a 24-year-old woman with a history of human papillomavirus (HPV) type 11 since childhood originating in the larynx and trachea, then progressing to involve the distal pulmonary alveoli and right middle ear through the eustachian tube.
  • Papillomatous growth was treated with multiple surgeries including laser cytoreduction of laryngotracheal papillomatosis and radical mastoidectomy, followed by a trial of chemotherapy.
  • Despite this aggressive treatment regimen, papillomatous growth progressed with recurrence in the right eustachian tube, middle ear, and mastoid eventually extending to involve the calvaria and scalp.
  • RESULTS: The patient underwent a composite resection of involved tissues, including the scalp, auricle, and lateral temporal bone, with reconstruction using a latissimus dorsi free flap.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Human papillomavirus 11. Papilloma / pathology. Respiratory Tract Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Disease Progression. Female. Humans. Neoplasm Recurrence, Local. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20015762.001).
  • [ISSN] 1532-818X
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Kosaba S, Yamamoto K: [Carinal reconstruction with wide airway resection by a new technique]. Kyobu Geka; 2001 Jan;54(1):4-7
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 61-year man with tracheal stenosis by tracheal cancer, 6 tracheal rings, 2 left bronchial rings, total right main bronchus, for which carina was resected and reconstructed by a new technique and for a 69 year man with lung cancer in right upper lobe, for which right upper-middle bilobectomy, S6 segmental resection and circumferential pulmonary artery resection were performed.
  • The tracea, left main bronchus, and right basal segment bronchus were anastomosed by new technique and the right main pulmonary artery and basal segment artery was anastomosed subsequent to chemotherapy.
  • The new reconstructive method of carina permits simple anastomosis, the possibility of carina reconstruction even in the case of wide airway resection and loss tension at the site of anastomosis.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Neoplasms, Multiple Primary / surgery. Reconstructive Surgical Procedures / methods. Trachea / surgery. Tracheal Neoplasms / surgery
  • [MeSH-minor] Aged. Anastomosis, Surgical / methods. Humans. Lung Neoplasms / surgery. Male. Middle Aged. Neoplasm Invasiveness. Pneumonectomy. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11197908.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Matsumura Y, Tanida T, Sato M, Sagawa M, Kumagai M, Sado T, Okada Y, Sakurada A, Handa M, Fujimura S, Kondo T: [New approaches for excellent operative field during tracheobronchial anastomoses in sleeve pneumonectomy: cardiopulmonary bypass and diseased lung ventilation]. Kyobu Geka; 2001 Jan;54(1):24-30
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two cases of left sleeve pneumonectomy (SP) were performed for bronchial gland carcinoma through clamshell incisions.
  • The postoperative courses of these patients were uneventful, although they developed temporary pulmonary edema that needed mechanical ventilation and appropriate diuretics for several days.
  • One case of patient with squamous cell carcinoma after chemotherapy was successfully treated by right SP through midline sternotomy.
  • [MeSH-major] Bronchi / surgery. Cardiopulmonary Bypass. Lung Neoplasms / surgery. Pneumonectomy / methods. Respiration, Artificial / methods. Trachea / surgery
  • [MeSH-minor] Adult. Aged. Anastomosis, Surgical / methods. Female. Humans. Male. Middle Aged. Reconstructive Surgical Procedures. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11197905.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


20. Le Péchoux C, Baldeyrou P, Ferreira I, Mahé M: [Thoracic adenoid cystic carcinomas]. Cancer Radiother; 2005 Nov;9(6-7):358-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenoid cystic carcinomas in the trachea are rare, but represent around 40% of all tracheal tumours.
  • Adenoid cystic carcinoma's growth rate is slow so that it is frequently diagnosed at an advanced stage.
  • Treatment in limited tumours is based upon surgical resection often combined to radiotherapy because of close surgical margins.
  • Radiotherapy dose may vary between 45 and 65 Gy according to margins status.
  • Among inoperable patients treated with exclusive radiotherapy for tracheal tumours (including adenoid cystic but also squamous cell carcinomas of poorer prognosis), the recommended delivered dose should be over 60 Gy.
  • They are considered chemo-resistant and targeted therapies may prove to be effective in the future.
  • [MeSH-major] Carcinoma, Adenoid Cystic / radiotherapy. Carcinoma, Adenoid Cystic / surgery. Tracheal Neoplasms / radiotherapy. Tracheal Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Drug Resistance, Neoplasm. Humans. Neoplasm Metastasis. Prognosis. Radiotherapy, Adjuvant. Survival

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16168695.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 19
  •  go-up   go-down


21. Takemura M, Osugi H, Lee S, Taguchi S, Kaneko M, Tanaka Y, Fukuhara K, Fujiwara Y, Nishizawa S, Kinoshita H: [Resection of esophageal cancer infiltrating the left main bronchus following complete response to preoperative radiochemotherapy--a case report]. Gan To Kagaku Ryoho; 2003 Nov;30(12):1949-53
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient was a 57-year-old man, who was found to have esophageal squamous cell carcinoma of the middle thoracic esophagus during a work-up of dysphagia.
  • After radiochemotherapy (liniac irradiation + low-dose FP therapy), the esophageal and bronchial lesion became smaller.
  • Bronchoscopic ultrasonography showed a clear boundary between the membranous portion of the trachea and the esophageal wall.
  • It is necessary to verify the effectiveness of surgical resection, as a secondary treatment, by accumulating data on cases such as the present one.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bronchial Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Esophagectomy
  • [MeSH-minor] Cisplatin / administration & dosage. Dose-Response Relationship, Drug. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14650965.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


22. Takemura M, Osugi H, Lee S, Nishikawa T, Fukuhara K, Iwasaki H: [Pathologic complete response of thoracic esophageal cancer developing after gastrectomy to neoadjuvant low-dose nedaplatin (CDGP), 5-fluorouracil and radiotherapy]. Gan To Kagaku Ryoho; 2005 Jul;32(7):1023-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We treated a 69-year-old man who had developed esophageal cancer following gastrectomy.
  • The cancer located in the middle of the thoracic esophagus, had invaded the trachea and metastasized to cervical lymph nodes according to computed tomography.
  • The esophageal cancer was found by endoscopy to have diminished significantly after completion of neoadjuvant therapy, An endoscopic biopsy specimen was found to contain no malignant cells.
  • Neoadjuvant chemoradiotherapy using low-dose CDGP/5-FU is an effective treatment for esophageal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Gastrectomy
  • [MeSH-minor] Aged. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Male. Neoadjuvant Therapy. Organoplatinum Compounds / administration & dosage. Remission Induction

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16044966.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


23. Santos RS, Raftopoulos Y, Keenan RJ, Halal A, Maley RH, Landreneau RJ: Bronchoscopic palliation of primary lung cancer: single or multimodality therapy? Surg Endosc; 2004 Jun;18(6):931-6
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bronchoscopic palliation of primary lung cancer: single or multimodality therapy?
  • BACKGROUND: An obstructing primary lung cancer is a challenging disease frequently requiring endobronchial interventional therapy.
  • A variety of interventional modalities, including Nd:YAG laser, stenting, photodynamic therapy (PDT), and endoluminal brachytherapy, are utilized to relieve airway obstruction and bleeding.
  • In 29 patients (42%) a multimodality endoscopic treatment was utilized (group B).
  • Single-modality treatment in group A included Nd-YAG laser in 60%, stent in 17%, brachytherapy in 20%, and PDT in 3%.
  • Patient data were compared with the Student's t-test and chi-square test.
  • The tumor was located in the trachea 9%, in the carina in 7%, and primary bronchial in 84%.
  • There was no significant difference between the two groups in relation to age, gender, tumor location, histology, and type of previous cancer therapy.
  • CONCLUSIONS: Improvement in survival can be seen with diligent airway surveillance after interventional bronchoscopy and liberal use of a variety of endobronchial treatment modalities for airway obstruction or bleeding.
  • Physicians involved in the management of this difficult problem should be versed in the use of all available treatment modalities to enhance therapeutic outcome.
  • [MeSH-major] Bronchoscopy. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Palliative Care / methods
  • [MeSH-minor] Aged. Airway Obstruction / etiology. Brachytherapy. Bronchial Neoplasms / complications. Bronchial Neoplasms / drug therapy. Bronchial Neoplasms / radiotherapy. Bronchial Neoplasms / surgery. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Combined Modality Therapy. Female. Hemoptysis / etiology. Humans. Laser Therapy. Life Tables. Male. Middle Aged. Photochemotherapy. Pneumonectomy. Retrospective Studies. Stents. Survival Analysis. Survival Rate. Tracheal Neoplasms / complications. Tracheal Neoplasms / drug therapy. Tracheal Neoplasms / radiotherapy. Tracheal Neoplasms / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest Surg Clin N Am. 2001 Nov;11(4):841-60 [11780299.001]
  • [Cites] Ann Thorac Surg. 1989 Oct;48(4):469-73; discussion 473-5 [2478088.001]
  • [Cites] Addiction. 2002 Dec;97(12):1561-71 [12472640.001]
  • [Cites] Clin Chest Med. 1995 Sep;16(3):445-54 [8521699.001]
  • [Cites] Ann Thorac Surg. 1995 Jun;59(6):1417-22 [7539606.001]
  • [Cites] Clin Chest Med. 2002 Mar;23(1):241-56 [11901914.001]
  • [Cites] Chest. 1991 May;99(5):1062-5 [2019157.001]
  • [Cites] Chest. 1999 Oct;116(4):1108-12 [10531180.001]
  • [Cites] Chest. 1984 Jul;86(1):8-13 [6734298.001]
  • [Cites] Ann Thorac Surg. 1994 Apr;57(4):1031-2 [8166507.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] Chest. 1994 Jun;105(6):1668-72 [7515777.001]
  • [Cites] Chest. 1996 Dec;110(6):1536-42 [8989073.001]
  • [Cites] Surg Endosc. 1998 Dec;12(12):1419-23 [9822470.001]
  • [Cites] Mayo Clin Proc. 1982 Sep;57(9):543-7 [7109682.001]
  • [Cites] Lung Cancer. 2000 Mar;27(3):169-75 [10699690.001]
  • [Cites] Surg Clin North Am. 2002 Jun;82(3):621-42 [12371589.001]
  • [Cites] Chest. 1984 Aug;86(2):163-8 [6547662.001]
  • (PMID = 15108108.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 21
  •  go-up   go-down


24. Bast F, Risteska K, Jovanovic S, Sedlmaier B: [The topical application of mitomycin C in the treatment of scar formation and stenosis in hollow organs of the head and neck: a field report]. Laryngorhinootologie; 2009 Aug;88(8):528-33
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The topical application of mitomycin C in the treatment of scar formation and stenosis in hollow organs of the head and neck: a field report].
  • Besides its use as an adjunction in the treatment of breast, lung and prostate cancer, or as a second-line cytostatic drug for head and neck squamous cell carcinoma (HNSCC), since 1963, MMC has also been successfully used in the suppression of post-operative scar formation, particularly in the field of ophthalmology.
  • In this résumé, we wish to recapitulate our long years of experience in the topical application of Mitomycin C in the treatment of scar formation and stenosis in head and neck organs.
  • The fields of application included laryngeal, tracheal, oesophageal stenosis and stenosis of the external ear canal and the choane.
  • RESULTS: After combined application of MMC and surgical intervention in cases of recurrent stenosising processes in head and neck organs, especially the larynx and the trachea, a sustained improvement was achieved in the pre-operative stenosis level as well as in the pre-operative, severely limited, forced inspiratory volume in 1 second (F1V1).
  • CONCLUSION: The topical application of MMC appears to be an effective adjunction as a concept of treatment for stenosising, scar-forming lesions.
  • This topical application, however, is not a substitute for correct diagnosis and appropriate surgical treatment.
  • [MeSH-major] Airway Obstruction / drug therapy. Antibiotics, Antineoplastic / administration & dosage. Cicatrix / drug therapy. Mitomycin / administration & dosage. Postoperative Complications / drug therapy
  • [MeSH-minor] Administration, Topical. Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Inspiratory Capacity / drug effects. Laryngoscopy. Laryngostenosis / diagnosis. Laryngostenosis / drug therapy. Laryngostenosis / surgery. Laser Therapy. Male. Middle Aged. Recurrence. Reoperation. Retreatment. Retrospective Studies. Tracheal Stenosis / diagnosis. Tracheal Stenosis / drug therapy. Tracheal Stenosis / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Choking.
  • MedlinePlus Health Information. consumer health - Scars.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart, New York.
  • (PMID = 19554503.001).
  • [ISSN] 1438-8685
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down






Advertisement